[Vitaherpavac is the first Russian herpes simplex virus vaccine obtained on the Vero B continuous cell line].
- O. A. Barkhaleva, I. P. Ladyzhenskaia, I. F. Barinskiĭ
- MedicineVoprosy virusologii
- 1 September 2009
Positive results have yielded that suggest that it is expedient to introduce of the new vaccine Vitaherpavac into practice to treat chronic recurrent herpetic infection of various localizations.
Effectiveness of Specific Prevention of Tick-Borne Encephalitis
- M. S. Shcherbinina, O. A. Barkhaleva, O. Dorokhova, A. Movsesyants
- Medicine, BiologyBIOpreparations. Prevention, Diagnosis, Treatment
- 18 September 2020
It was demonstrated that the use of vaccines for prevention of TBE is effective, provided the vaccination coverage is not less than 80%; further studies are needed to assess TBE vaccine efficacy in order to improve vaccination tactics, to better understand causes of morbidity and mortality among vaccinated individuals.
xperimental Evaluation of the Possibility of using the LAL test to Determine Bacterial Endotoxins in Vaccines for Rabies Prophylaxis
- A. Muhacheva, O. A. Barkhaleva, K. Sarkisyan
- MedicineEpidemiology and Vaccinal Prevention
- 5 November 2021
The research proved the possibility of determining bacterial endotoxins by methods: gel-clot test, turbidimetric kinetic test, and chromogenic kinetic test (method D).